ARTIMPLANT INTERIM REPORT JANUARY – JUNE 2007

Västra Frölunda, Sweden, August 8, 2007

• Net revenue of SEK 8.7 million (3.0)*
• Net loss of SEK -7.7 million (-30.7)
• Net loss of SEK -6.1 million (-19.1) excluding a non-recurring item of SEK -1.6 million (-11.6)
• Earnings per share, including non-recurring item, of SEK -0.13 (SEK -0.52)
• Sales for Artelon® CMC Spacer – approximately 2,100 (900) units were sold to end-customers, of which 800 (500) were during Q2 2007
• Since the launch approximately 5,000 patients have been treated with Artelon® implants
• FDA clearance for marketing for Artelon® CMC Spacer Arthro and Artelon® STT Spacer
• A head of marketing has been appointed and will commence on October 1

* Figures in brackets refer to the corresponding period last year.

Artimplant will host a conference call in Swedish at 2:30 PM Central European Time (GMT+1). Log on details are available on www.artimplant.com.

Please note that Artimplant´s nine-monthly report will be presented one day later than earlier communicated on November 9, 2007.